Schizophrenia is a chronic debilitating multifactor disorder of mind with a constant prevalence of 1-2% in the population (Yue Hou et al., 2013; Uma Devi et al., 2014; Nandini et al., 2010) and characterized by profound disturbance of perception, cognition, emotion, and social function (Uma Devi et al., 2014). The glutamate receptor theory indicates the involvement of glutamate receptors in pathophysiology of mood disorders (Mahajan et al., 2013; Uma Devi et al., 2014). Hypofunctional N-methyl-D-aspartate (NMDA) receptor signaling, particularly in the prefrontal cortex, has been implicated in the cognitive and behavioral disturbances seen in schizophrenia. Exposure to non-competitive NMDA receptor antagonists, such as phencyclidine (PCP) and ketamine, induces a broad range of antipsychotic sensitive and schizophrenia-like behavioral abnormalities in healthy individuals and exacerbates the same symptoms in schizophrenic patients. These

Schizophrenia-like behaviors have been attributed to the blockade of synaptic NMDA receptors by these drugs (Chan et al., 2012).

Drugs prescribed for the treatment of psychosis can be categorized as typical and atypical. The typical classes of antipsychotics are effective against the positive symptoms, i.e. hallucinations, delusions, etc. and also possess extra-pyramidal side effects. Whereas the atypical class are effective in ameliorating the positive, negative as well as the cognitive symptoms and possess lesser extra-pyramidal side effects but in turn hold greater risk of cardiovascular diseases, diabetes and agranulocytosis etc. Regular intake of these agents may also increase oxidative load and thereby further enhance the progression of the disease. In a scenario like this we need drugs with lesser side effects (Chatterjee et al., 2011). Pterostilbene is a phenolic compound chemically similar to resveratrol (Remsberg et al., 2008). Initially

1. Introduction

Schizophrenia is a chronic debilitating multifactor disorder of mind with a constant prevalence of 1-2% in the population (Yue Hou et al., 2013; Uma Devi et al., 2014; Nandini et al., 2010) and characterized by profound disturbance of perception, cognition, emotion, and social function (Uma Devi et al., 2014). The glutamate receptor theory indicates the involvement of glutamate receptors in pathophysiology of mood disorders (Mahajan et al., 2013; Uma Devi et al., 2014). Hypofunctional N-methyl-D-aspartate (NMDA) receptor signaling, particularly in the prefrontal cortex, has been implicated in the cognitive and behavioral disturbances seen in schizophrenia. Exposure to non-competitive NMDA receptor antagonists, such as phencyclidine (PCP) and ketamine, induces a broad range of antipsychotic sensitive and schizophrenia-like behavioral abnormalities in healthy individuals and exacerbates the same symptoms in schizophrenic patients.
isolated from sandalwood and other natural sources of pterostilbene are various herbal drugs, for example, leaves and grapes of Vitis vinifera, Vaccinium spp., and Pterocarpus marsupium (Grover et al., 2005; Langcake et al., 1979; Paul et al., 1999). It is also found in fruits including grapes and blueberries, known for their beneficial effects on learning and memory impairment possibly via inhibiting microglia activation and protecting neuronal injury in mice (Hou et al., 2014) and neuronal function during aging. It is a potent antioxidant and anti-inflammatory agent shown to have beneficial effects in methamphetamine-induced hyperactivity, (Miller et al., 2013) hyperglycemia, (Satheesh and Pari, 2008; Manickam et al., 1997) the aging brain and in Alzheimer’s disease (Joseph et al., 2008; Remsberg et al., 2008; Rimando et al., 2002; Chang et al., 2012). Interestingly, in vitro, it has higher potency at inducing apoptosis in cancer cells than resveratrol (Mikstacka et al., 2007), and shows powerful agonistic properties on the peroxisome proliferator activated receptor (PPAR) alpha receptor (Rimando et al., 2005; Satheesh and Pari, 2008) a receptor complex that is intimately associated with fatty acid metabolism, inflammation, and oxidative stress regulation, and antagonistic properties on GSK3β in GSK3β/β-catenin pathway (Chen et al., 2014). In this study our hypothesis is that pterostilbene protects from schizophrenia by acting on GSK3β signaling pathway and rescues ketamine induced behavioural changes and oxidative stress.

2. Materials and methods:

2.1. Experimental animals

Swiss albino mice, weighing 20-35g, at the age 3-4 weeks were used in the study. They were maintained on standard laboratory pellet chow diet; Provimi limited (India), provided water ad libitum and were kept under standard conditions at 23-25 °C, 35 to 60% humidity, and 12hr light/dark cycle. The mice were acclimatized to the laboratory conditions a week prior to experiment. The experimental protocol was duly approved by institutional animal ethics committee (IAEC) and care of the animals was carried out as per the guidelines of committee for the purpose of control and supervision of experiments on animals (CPCSEA) (Protocol No: I/IAEC/LCP/003/2014/SM/30).

2.2. Drugs and chemicals

Pterostilbene was gift sample from SAMI LABS Bangalore, India. Ketamine was purchased from local hospital, hyderabad. DTNB (5,5’-dithiobis(2-nitrobenzoicacid)), Eserine, Acetylthiocholine iodide, Reduced Glutathione were purchased from Sigma Aldrich, USA. 2-Thiobarbituric acid was purchased from Himedia laboratories Pvt Ltd, Mumbai. All other reagents of Analytical grade are from S. D Fine chemicals Ltd, India.

2.3. Induction of Schizophrenia and grouping/Experimental protocol

Schizophrenia is induced by chronic administration of Ketamine (50 mg/kg/day) for 14 days.

Animals were randomly divided into five groups of each six mice. Group I: vehicle control received 0.5% CMC(carboxy methyl cellulose) (p.o), Group II: ketamine control received only with Ketamine(i.p), Group III and IV animals were injected with Ketamine and treated with 10 and 20mg/kg (p.o) Pterostilbene (PTR). Except vehicle control group all the animals received Ketamine injection for 14 days.

2.4. Behavioural assessment

2.4.1. Locomotor activity

Spontaneous locomotor activity was measured in actophotometer having dimensions of 39x28x26 cm. The breakage of photobeams was monitored with infrared sensors and automatically recorded for 5min (Elder et al., 2008).

2.4.2. Video tracking in Y Maze

Y-maze task used to measure the spatial working memory in mice. The maze is made of gray plastic. Each arm is 40 cm long, 13 cm high, 3 cm wide at the bottom, 10 cm wide at the top, and converged at an equal angle. Each mouse was placed at the end of one arm and allowed to move freely through the maze for 8 mins. Mice tend to explore the maze systematically, entering each arm in turn. The ability to alternate requires that the mice know which arm they have already visited. The series of arm entries, including possible returns into the same arm is recorded. Alteration is defined as the successive entries into the three arms, on overlapping triplet sets. The percentage of alteration is calculated as the ratio of actual alterations to possible alterations, defined as the total number of arm entries minus two, and multiplied by hundred. Typically, mice exhibit an alteration percentage of 60-70%, and perform 25-35 arm entries within the 8 min session (Sharath et al., 2016).

2.4.3. Open field habituation

The exploratory behaviour of the mice was evaluated by open field habituation task method. Mice was placed in a 40 cmx50 cmx60 cm open field whose brown linoleum floor was divided into 12 equal squares by white lines and left to explore it freely for 5 minutes. The number of line crossings and head dippings were counted (Maria et al., 2005, Fendt et al., 2008).

2.4.4. Forced swimming test

The forced swimming test was performed as previously reported (Noda et al., 1997, Noda et al., 2000). In brief, mice were placed individually in glass cylinders (20 cm height, 12 cm diameter) containing 10 cm depth of water at 25 °C. After 5 min, the animals were removed from water, dried and returned back to their home cages. They
were again placed in the cylinder 24 h later and the total
duration of immobility was measured for 3 min. Mice
which were floating motionless were considered to be
immobile.

2.5. Biochemical Estimations

2.5.1 Estimation of Acetylcholinesterase

Brain tissue was homogenized in Phosphate buffer (pH 8,
0.1 M) in a Potter Elvehjem homogenizer. 0.5 ml of
supernatant liquid of the brain homogenate was pipetted
out into 25 ml volumetric flask and dilution was made
with a freshly prepared DTNB solution (10 mg DTNB in
100 ml of Sorenson phosphate buffer, pH 8.0). From the
volumetric flask, two 4 ml portions were pipette out into
two test tubes. Into one of the test tube, 2 drops of
eserine solution was added. 1 ml of substrate solution (75
mg of acetylcholine iodide per 50 ml of distilled water)
was pipetted out into both of the test tubes and incubated
for 10 min. at 30°C. The solution containing eserine
solution was used for zeroing the colorimeter and change
in absorbance per min. of the sample was read
spectrophotometrically (UV-1800, Shimadzu) at 420 nm.
The enzyme activity is expressed as μmoles/minute/mg
protein (Avinash et al., 2016).

2.5.2. Estimation of Reduced Glutathione (GSH)

GSH was determined by its reaction with 5, 5-dithiobis
(2-nitrobenzoic acid) (Ellman’s reagent) to yield a yellow
chromophore which was measured spectrophotometrically. The brain homogenate
was mixed with an equal amount of 10% trichloroacetic acid
(TCA) and centrifuged (Remi cold centrifuge) at 2000xg
for 10min at 4°C. To 0.1 ml of processed tissue sample,
2ml of phosphate buffer (pH 8.4), 0.5 ml of 5, 5-dithiobis
(2-nitrobenzoic acid) (DTNB) and 0.4 ml of double-
distilled water were added and the mixture was shaken.
The absorbance was read at 412nm within 15 min
(Santhosh kumar et al., 2010).

2.5.3 Estimation of catalase

Blank 1: buffer 1 ml – this only for blanking the
instrument.
Blank 2: 1ml H2O2 + 100 μl buffer + 1 ml ammonium
molybdate. – Read at 405nm
Blank 3: 1.1 ml buffer + 1 ml ammonium molybdate –
read at 405nm
Add 1 ml of H2O2 to 100 μl of Sample and mix well,
after 60 seconds add 1 ml ammonium molybdate and
read the absorbance at 405 nm (Goth., 1991). One unit of
the enzyme was defined as millimoles of H2O2
degraded/min/milligram of protein.

2.5.4 Estimation of superoxide dismutase

For monitoring pyrogallol auto-oxidation, 20 to 80 μl of
pyrogallol was pipetted out and the volume was made up
to 100 μl with 0.01 N HCl. To this 600μl of Tris –HCl
buffer, 100μl of DETPA, 100 μl of Tris EDTA and
100μl of distilled water was added. For the sample assay,
50μl of pyrogallol and 50μl of the sample were added
and the reaction was initiated & measured at 420 nm at a
constant temperature of 25°C for 3min at 0.5 nm
bandwidth. One unit SOD activity is the amount of
enzyme that inhibits the rate of auto-oxidation of
pyrogallol by 50 percent (Maneesha Ram et al., 2016).

2.5.5 Estimation of Brain Thiobarbituric acid reactive
species (TBARS)

The whole brain TBARS level was measured by the
method of (Ohokawa et al., 1979) with slight
modifications. To 0.2 ml brain homogenate, 0.2 ml
sodium dodecyl sulphate (SDS), 1.5 ml of 30% acetic
acid (pH-3.5), were added and made up the volume up to
4.0 ml with distilled water (DW) and incubated at 95 °C
for 60 min.1.0 ml of DW and 5.0 ml of 30% acetic
acid (pH-3.5), was added and centrifuged at the 4000 ×g
for 10 min. The absorbance of developed colour in organic
layer was measured spectrophotometrically at 532 nm.
The absorbance from a standard curve generated using
1,1,3,3, tetra-methoxy propane as standard was
extrapolated (Sharma et al., 2008, Ohokawa et., 1979).

2.6 Statistical analysis:

All data are presented as Mean ±S.E.M. The significance
of difference among the groups were assessed using
one way analysis of variance(ANOVA) followed by
Tukey’s test using Graph pad PRISM software and
p<0.05 was considered significant.

3. Results

3.1. Effect of pterostilbene on locomotor activity using
actophotometer :

Schizophrenia was assessed by locomotor activity in
Actophotometer and the effect of pterostilbene on
locomotor activity were shown in Fig: 1. Administration
of ketamine showed significant (P < 0.001) increase in
locomotor activity in Group II when compared with
Group I, Group III and IV showed significant (P <
0.001) decrease in locomotor activity when compared
with Group II.

Fig. 1: Effect of pterostilbene on locomotor activity

Values are expressed as mean ± SEM of n=6 animals.
Superscript letters represents the statistical significance
done by ANOVA, followed by Tukey’s tests.
3.2. Effect of pterostilbene on Y-Maze activity

Fig: 2 shows the results for the performance of mice in Y-Maze task in which spatial recognition memory performance as alternation behaviour can be examined. The percentage alterations of Group II significantly (P < 0.001) lowered when compared with Group I, there was a significant (P < 0.01,) and (P <0.001) increase in percentage alterations in Group III and Group IV when compared with Group II.

3.3. Open field habituation test

Effect of pterostilbene on open field exploration were shown in Fig: 3 and Fig: 4. The exploratory behaviour (i.e.) the number of line crossings and nose poking increased significantly (P < 0.001) in Group II on comparison with Group I. Group III and Group IV showed significant (P <0.001) and (P < 0.001) decrease in line crossings and nose poking when compared with Group II.

3.4. Forced swim test activity

Fig: 5 shows the effect of pterostilbene on the duration of immobility in forced swim test. The duration of immobility was increased significantly (P < 0.001) in Group II on comparison with Group I. Group III and Group IV showed significant (P <0.01) and (P < 0.001) decrease in the duration of immobility when compared with Group II. There observed statistical significance (P < 0.01) among Group I and Group III, Group III and Group IV (P < 0.001).

3.5 Reduced Glutathione (GSH)

The results were shown in Table 1. The GSH levels were significantly (P < 0.001) decreased in Group II when compared with vehicle control; ***P<0.001, Compared with Negative Control.
compared with Group I. There was observed significant (P < 0.05) and (P < 0.001) increase in enzyme levels in Group III and Group IV on comparison with Group II.

### 3.6 Catalase enzyme activity

The catalase levels were shown in Table 1. The enzyme levels were significantly (P < 0.05) decreased in Group II when compared with Group I, there was a significant (P < 0.05) and (P < 0.05) increase in catalase activity in Group III and Group IV when compared with Group II.

### 3.7 Superoxide dismutase (SOD)

The effect of pterostilbene on anti-oxidant enzyme SOD was shown in Table 1. The enzyme levels were significantly (P < 0.001) decreased in Group II when compared with Group I, there was a significant (P < 0.001, P <0.001) increase in enzyme levels in Group III and Group IV when compared with Group II (P < 0.001).

### 3.8. Thiobarbituric acid reactive species (TBARS)

Effect of pterostilbene on lipid peroxidation markers were shown in Table 1. The brain TBARS significantly (P < 0.05) increased in Group II when compared with Group I. Group III and Group IV significantly (P < 0.05) and (P <0.05) decreased TBARS when compared with Group II.

### 3.9. Acetyl cholinesterase enzyme activity

Effect of pterostilbene on AchE was depicted in Table 1. Administration of ketamine significantly (P < 0.001) increased the AchE activity when compared with Group I, Group III and Group IV significantly (P < 0.001) and (P < 0.001) attenuated the raise in enzyme level when compared with Group II.

Table 1: Effect of pterostilbene on Biochemical estimations

<table>
<thead>
<tr>
<th>Groups</th>
<th>GSH (U/mg protein)</th>
<th>Catalase (U/mg protein)</th>
<th>SOD (U/min/mg protein)</th>
<th>TBARS (nmol/mg protein)</th>
<th>AchE (µmol/min/mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I (Vehicle)</td>
<td>0.19 ±0.02</td>
<td>0.16 ±0.02</td>
<td>22.82±2.06</td>
<td>3.41±0.31</td>
<td>1.64±0.27</td>
</tr>
<tr>
<td>Group II (KET 50 mg/kg)</td>
<td>0.02±0.00 ***</td>
<td>0.07±0.00 *</td>
<td>1.59±0.19 **</td>
<td>5.22±0.55 *</td>
<td>6.82±0.17 ***</td>
</tr>
<tr>
<td>Group III (PTR10mg/kg+KET)</td>
<td>0.11±0.01 #</td>
<td>0.15±0.01 #</td>
<td>12.87±0.94 #**</td>
<td>5.12±0.42 #</td>
<td>3.69±0.19 #**</td>
</tr>
<tr>
<td>Group IV (PTR20mg/kg+KET)</td>
<td>0.17±0.02 ***</td>
<td>0.16±0.02 $</td>
<td>20.35±2.02 **$</td>
<td>3.25±0.36 $</td>
<td>2.25±0.26 **$</td>
</tr>
</tbody>
</table>

Values are expressed as mean ± SEM of 6 animals. Superscript symbols represent the statistical significance done by ANOVA, followed by Tukey’s multiple comparison tests. ***p<0.001, **p<0.01, *p<0.05 indicates comparison of negative control group with control group. ###p<0.001, #p<0.01, $p<0.05 indicates comparison with ketamine control.

### 4. Discussion

Schizophrenia is a chronic debilitating psychiatric disorder affecting as many as 1% of the population worldwide (Silveri Kalpana et al., 2013). The clinical features of the heterogeneous disorder schizophrenia usually appear in late adolescence or early adulthood, and can be divided into positive, negative and cognitive symptoms. Delusions (paranoia, false beliefs), hallucinations (visual and auditory), and thought disturbances are classified as positive symptoms, whereas negative features include depression, withdrawal from social contacts, incapability to feel pleasure (anhedonia) and flattening of emotional responses. Cognitive defects involve deficits in attention and memory (Rajiv Tendon et al 2009).

The residual symptoms especially negative and cognitive symptoms are closely correlated with the degree of disability than the positive symptoms (Buckley et al., 2007). Atypical antipsychotic medication provides hope in the management of negative symptoms, but the success remains limited. (Silveri Kalpana et al. 2013). The dopaminergic hypothesis came about from the observation that drugs that antagonized dopamine were found to be effective in the treatment of schizophrenia. Dopamine system has been proposed to account for the positive and negative symptoms of schizophrenia that emerge during adolescence. Dopamine antagonists are effective only in treating positive symptoms associated in schizophrenia (Howes et al., 2009).

The goal of the study was to assess the efficacy of pterostilbene using ketamine-induced schizophrenia
model in mice with respect to some selected behavioural phenotypes that correlate with certain sections of symptoms observed in schizophrenia. In the present study the behavioural models such as locomotor activity, forced swimming test, Y-maze tests were conducted and Acetylcholinesterase enzyme, TBARS, SOD, CAT and GSH levels in brain tissue were estimated.

Locomotor activity is a measure of the positive symptoms in schizophrenia. Positive symptoms include aggressive and stereotype behaviour. Results in the present study indicate that chronic treatment of ketamine (50 mg/kg, i.p.) produced hyper locomotor response. It has been reported that dopaminergic pathways are critical for the control of locomotor activities. Ketamine increased the dopamine levels (Chattherjee et al, 2011). The locomotor activity was almost normal when high and low dose of pterostilbene was given in ketamine induced mice and it is an indication of protection from the occurrence of positive symptoms in schizophrenia.

Forced swim-induced immobility in rodents is an acceptable animal model of schizophrenia that reflects a state of despair in the rat and the reduction in the immobility time serves as the index of antidepressant activity (Silveri Kalpana et al, 2013; Yue Hou et al.,2013; Daine B.Fraga et al.,2013). In our study chronic administration of ketamine for 14 days induced enhancement of the mobility duration of mice in forced swimming test. The reduction in mobility duration was significant when low dose and high dose of pterostilbene was given in ketamine received mice and it is an indication of protection from the occurrence of negative symptoms in schizophrenia.

Cognitive impairments such as deficits in attention, executive function, short-term memory, and long-term memory, are core symptoms in patients with schizophrenia. Among these, learning and memory impairments are known to be particularly severe, and they are suggested to be major determinants of the amount of disability in patients with schizophrenia (Yue Hou et al.,2013; Harvey et al.,2004; Saykin et al.,1991).

The active Y-maze task has been used to evaluate the effects of antipsychotic drugs on learning and memory function. Pterostilbene improved the ketamine induced cognitive symptoms in schizophrenic mice in our study.

Acetylcholine plays a critical synaptic role in the initial stages of memory formation. Ketamine blocks nicotinic cholinergic receptors and there by suppresses glutamate release. Blockade of these receptors, induces increased ACh release activating cholinesterase enzyme which, in turn, interferes with hippocampal memory formation (Silveri Kalpana et al, 2013). Pterostilbene reduced the Ache levels and produced potentiating effect.

Oxidative stress refers to an imbalance between the formation of cellular oxidants and the antioxidative processes and it occurs when the production of reactive oxygen radicals (or free radicals) increases beyond the physiological antioxidative protective mechanisms. It plays an important role in neuronal injury and schizophrenic pathophysiology (Bošković et al., 2011; Wu et al., 2013). Oxidative stress activates GSK3β in rodents (Jean-Martin Beaulieu., 2012). Different sub-anesthetic doses of ketamine increase oxidative stress in the brain of rodents (Oliveira et al.,2009). Recent studies have implicated GSK-3β signaling in schizophrenia (Kozlovsky et al., 2000; Emamian et al., 2004; Lovestone et al., 2007; Freyberg et al., 2010). Moreover, GSK-3β is a target for several antipsychotics that decrease the activity of GSK-3β by causing the phosphorylation of GSK-3β at Ser9 (Mahajan et al.,2013; Kozlovsky et al., 2006). In fact, the NMDA receptor antagonists PCP and MK-801 have been found to increase GSK-3β activity both in vitro (Elyaman et al.,2002) and in vivo. We measured the amount of SOD, TBARS, GSH, CAT and AchE in brain of mice treated with repeated ketamine. Both high and low doses of pterostilbene reduced the oxidative stress.

5. Conclusion

Schizophrenia is a chronic and disabling mental illness affecting millions of people worldwide. The symptoms of schizophrenia are classified into positive, negative and cognitive symptoms. New receptor targets and drugs have been evaluated for addressing the multifaceted syndrome of schizophrenia. The results suggest that the drug pterostilbene could be a new third-generation therapeutic agent for treating schizophrenia.

6. References


How to cite this article: